Home

PMV Pharmaceuticals, Inc. - Common Stock (PMVP)

1.4350
-0.0050 (-0.35%)

PMV Pharmaceuticals Inc is a biotechnology company focused on the discovery and development of novel therapies that target specific genetic mutations in cancer

The company utilizes its proprietary platform to identify and design small molecule drugs aimed at treating a range of cancers by addressing the underlying genetic drivers of the disease. With a strong emphasis on precision medicine, PMV Pharmaceuticals strives to improve patient outcomes through innovative treatments that can selectively target and inhibit tumor growth associated with particular genetic alterations.

SummaryNewsPress ReleasesChartHistoricalFAQ
“Game-Changing Biotech Companies Making Waves: INBS, PMVP, TPST, OMGA, MRSN”
In the rapidly evolving biotech sector, a few standout companies are pushing boundaries and setting new standards. From Intelligent Bio Solutions' innovative drug testing technology to PMV Pharmaceuticals' promising clinical trial advancements, these trailblazers are not just making headlines—they're shaping the future of healthcare while improving the workplace. Discover how these five companies are leading the charge in innovation, with significant developments that could impact industries and lives worldwide.
Via AB Newswire · August 16, 2024
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation.
By Foundation Medicine · Via Business Wire · May 29, 2024